IDH2 and central nervous system cancer: Approximately two-thirds of the IDH-mutant gliomas have an intact 1p/19q, and of these 94% have TP53 loss of function or other mutation and 86% have ATRX inactivation, which is involved in chromatin remodeling and DNA methylation (Brat et al., 2015).